HRC 102Alternative Names: HML 110
Latest Information Update: 05 Sep 2007
At a glance
- Originator Hemosol Corp
- Developer Hemosol Corp (CEASED)
- Mechanism of Action Oxygen carriers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hypoxia
Most Recent Events
- 30 Jan 2004 HRC 102 is available for licensing (http://hrc.hemosol.com)
- 03 Jan 2002 Preclinical development for Acute hypoxia in Canada (Unknown route)